BioLife Sciences retains Benzinga for its marketing campaign
HENDERSON, Nev., Aug. 09, 2022 (GLOBE NEWSWIRE) — BioLife Sciences Inc. (OTCPK: BLFE) (the “Company” or BioLife), today announced that it has retained Benzinga to launch marketing and advertising on its network of media channels.
BioLife Sciences was recently qualified for an A+ (Level 1) regulatory offering by the SEC, aimed at meeting various business objectives and guidelines.
Nika Jaksic, COO of BioLife Sciences, said, “We chose to launch our marketing campaigns in phases, first using SmallCapVoice.com, then continuing with GS Whitney & Co, and now leveraging this solid foundation with Benzinga.com. , and their unionized partners, whose reach and expertise are unquestionable. Benzinga is one of the leading financial media that provides investors with highly informative and high quality content. We are delighted to have reached an agreement with them.
Benzinga, since its launch in 2010, has become a major hub for actionable capital market insights. With more than two million readers each month, Benzinga continues to empower new generations of investors by connecting the world to news, data and education, easing the path to financial prosperity for all.
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products from laboratory or small-scale production to wider market adoption. Its main activity is to develop, license and distribute antimicrobial products and disruptive technologies. One of BioLife Sciences’ core strategies is to develop, partner and help innovative companies bring cutting-edge technologies to market.
About Benzinga
Benzinga empowers individual investors by allowing them to stay one step ahead. Benzinga provides access to all available financial news and content. Instead of giving financial advice, Benzinga gives you the news to make informed decisions to take control of your financial future.
Disclaimer
The information in this press release includes certain information and statements about management’s views on future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based on assumptions subject to significant risks and uncertainties. Due to these risks and uncertainties and due to various factors, actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, the Company’s ability to complete a Qualifying Transaction. A number of factors could cause actual results to differ materially from these forward-looking statements and from future results. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the expectations in the forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and undertakes no obligation to update or revise forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting these forward-looking statements. – statements seeking or otherwise.
Contact information:
www.biolifesciences.com
ir@biolifesciences.com
USA and Canada: 1 (833) 919-1037
